fig1
![Overview of methodologies and statistical strategies in observational studies and meta-analyses on the risk of hepatocellular carcinoma in patients with chronic hepatitis B on entecavir or tenofovir therapy](https://image.oaes.cc/0db8cd42-8454-4bd8-877d-fb66f9f0f3ca/4600.fig.1.jpg)
Figure 1. Violin plots of propensity score (PS) (A) before and after (B) 1:1 nearest neighbor matching (caliper of 0.1 standard deviations of the logit of PS) and (C) weighting using average treatment effect of the treated (ATT) in a simulated cohort of 100 tenofovir disoproxil fumarate (TDF)-treated patients and 900 entecavir (ETV)-treated patients with chronic hepatitis B. PS was estimated by logistic regression of seven covariates to predict the use of TDF.